Background Dual anti‐platelet therapy including clopidogrel or prasugrel is standard of care
for patients receiving stents. Prasugrel has quicker onset so it can be loaded later than …

Background—The increasing use of higher-than-approved doses of clopidogrel in clinical
practice is based in part on the desire for greater levels of inhibition of platelet aggregation …

Objective Although several clinical trials have shown that the mid-and long-term safety and
efficacy of prasugrel are better than those of clopidogrel after percutaneous coronary …

Objectives: The aim of this study was to assess the safety of the concurrent administration of
a clopidogrel and prasugrel loading dose in patients undergoing primary percutaneous …

Prasugrel has been shown to be superior to clopidogrel in the setting of ACS patients
undergoing coronary angioplasty. However, few data have been reported so far on those …

Objective To determine the safety and efficacy of administering prasugrel at the time of
percutaneous coronary intervention (PCI), and switching to clopidogrel, without reloading …

Primary percutaneous coronary intervention (PCI) encompassing stent implantation is a
mainstay in the management of acute ST-elevation myocardial infarction (STEMI). Despite …

There are very few clinical data concerning the safety of switching from clopidogrel to
prasugrel in patients undergoing coronary stenting. However, in the daily activity, clinicians …

Antiplatelet therapy is one of the key initial therapeutic interventions to prevent thrombotic
complications associated with percutaneous coronary intervention. Aspirin and the …

Background Prasugrel is the most recent addition to the available thienopyridine antiplatelet
agents used to prevent ischemic events in patients with acute coronary syndrome …